Gilteritinib overcomes second‑generation TKIs resistance in ALK‑rearranged non‑small‑cell lung cancer by inhibiting PD‑L1 and CD8 co‑expressionHang Guo, Chunguang Wang, Chengyan Jin et al.|International Journal of Molecular Medicine|2026Cited by 0